logo
Think That DIY Acne Trick Is Helping? Here's What Dermatologists Want You to Know

Think That DIY Acne Trick Is Helping? Here's What Dermatologists Want You to Know

Yahoo27-05-2025

Board-certified dermatologist provides tips for clearer skin ahead of Acne Awareness Month
ROSEMONT, Ill., May 27, 2025 /PRNewswire/ -- Acne is one of the most common skin conditions, affecting nearly 85% of people at some point in their lives. With people increasingly turning to social media for skin care advice, at-home acne hacks have become viral, but not all are safe or effective.
Ahead of Acne Awareness Month in June, Michigan-based board-certified dermatologist Fatima Fahs, MD, FAAD, breaks down what really works and what could make things worse.
"Everyone's skin is different, and treating acne isn't a one-size-fits-all solution," said Dr. Fahs. "That's where expert care makes all the difference. A board-certified dermatologist can identify your specific type of acne and recommend the most effective treatment for your skin."
Different Types of Acne
Acne can appear in different ways, including blackheads, whiteheads, pimples, and deeper cysts or nodules. While it's not contagious, acne can significantly impact a person's self-esteem and, if left untreated, may lead to permanent scarring.
There are different types of acne, including the following common forms: cystic acne, fungal acne, and hormonal acne.
Cystic acne is a severe form of acne in which large, painful cysts form deep under the skin, according to Dr. Fahs. It develops when oil and dead skin cells clog your pores, which triggers inflammation and infection from bacteria. If untreated, it can lead to scarring, which is why it's important to consult with a board-certified dermatologist before it gets worse.
Not all acne, however, is caused by bacteria. "Fungal acne," known medically as Pityrosporum folliculitis, is caused by an overgrowth of yeast in hair follicles. It appears as a series of small bumps, typically on the forehead, chest, and upper back—areas with a lot of hair follicles—and tends get worse in hot, humid environments.
Hormonal acne is usually related to changes in hormone levels, particularly around the menstrual cycle, said Dr. Fahs. It typically appears as cystic or inflammatory bumps along the jawline, chin, and lower cheeks. Many patients may notice flare-ups just before their period begins.
"Understanding the way your acne behaves can help you and your dermatologist come up with a treatment plan that's suitable for your unique skin," she said. "Acne that tends to be hormonal requires treatment that is very different than acne caused by yeast overgrowth. Paying attention to what flares or improves your acne can be a helpful first step in addressing the issue."
Common Treatments
Common acne treatments include vitamin A-based products called retinoids that unclog pores, benzoyl peroxide to reduce bacteria, and salicylic acid to ease inflammation.
"When incorporating acne over-the-counter medications into your daily routine, try to keep the rest of your skin-care routine gentle to avoid irritation of the skin," said Dr. Fahs. "Most acne products can lead to dryness, so pairing them with gentle cleansers and moisturizers before and after use can ensure a healthy skin barrier."
For more severe cases, dermatologists may prescribe medications such as antibiotics, hormonal treatments like birth control pills and spironolactone that help reduce the effects of hormones on excess oil production, or isotretinoin, a powerful prescription medication used to treat acne when other treatments don't work.
"We approach each acne treatment based on severity and type of acne," said Dr. Fahs. "Each medication plays a different role, and the goal is always to find the most effective solution for that person's unique skin."
Online Hacks – Do They Work?
As social media continues to shape beauty and skincare routines, many acne-related trends have gone viral. While some have the potential to be helpful, Dr. Fahs warns that others may do more harm than good.
Chamomile tea is often touted for its anti-inflammatory properties. While drinking chamomile may offer some skin-calming benefits due to its flavonoids (a group of natural substances found in plants that help protect the body by reducing inflammation), there isn't enough evidence to support using it as an acne treatment, said Dr. Fahs.
"While I don't think it's harmful to drink a cup a night, I would recommend against using chamomile directly from tea bags on the skin, because it could cause irritation," she said. "Instead, opt for over-the-counter products that contain chamomile as an ingredient."
Other social trends like using dandruff shampoo on your face may have some truth behind them but can also cause problems, said Dr. Fahs. While dandruff shampoo can help with certain forehead bumps caused by yeast, it's not made for facial skin and can lead to dryness, irritation, and more breakouts if overused.
Saunas can boost blood flow and reduce stress, which might help some skin conditions, she said, but they can also make others worse and increase the risk of skin infections.
"On the flip side, pimple patches do have science behind them—they help draw out fluid from pimples and stop you from picking, but they won't work on deep acne," said Dr. Fahs. "With so many tips online, it's best to be cautious and make an appointment to see a board-certified dermatologist before trying new treatments."
To find a board-certified dermatologist in your area, visit aad.org/findaderm.
More InformationAcne Resource Center
About the AADHeadquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 21,000 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, TikTok, Pinterest and YouTube and @AADskin1 on Instagram.
Editor's note: The AAD does not promote or endorse any products or services. This content is intended as editorial content and should not be embedded with any paid, sponsored or advertorial content as it could be perceived as an AAD endorsement.
View original content:https://www.prnewswire.com/news-releases/think-that-diy-acne-trick-is-helping-heres-what-dermatologists-want-you-to-know-302465950.html
SOURCE American Academy of Dermatology

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Arthrosi Presents Positive Long-Term Safety and Efficacy Data for Pozdeutinurad (AR882) at the European Alliance of Associations for Rheumatology (EULAR) Congress 2025
Arthrosi Presents Positive Long-Term Safety and Efficacy Data for Pozdeutinurad (AR882) at the European Alliance of Associations for Rheumatology (EULAR) Congress 2025

Associated Press

time27 minutes ago

  • Associated Press

Arthrosi Presents Positive Long-Term Safety and Efficacy Data for Pozdeutinurad (AR882) at the European Alliance of Associations for Rheumatology (EULAR) Congress 2025

Data demonstrates that pozdeutinurad alone or in combination achieves significant reduction in sUA levels in patients with tophaceous gout up to 18 months of treatment Pozdeutinurad's long-term use was well tolerated and comparable to standard of care, with no incidences of elevated serum creatine or clinically significant liver function abnormalities SAN DIEGO, June 12, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares, and dissolve tophi in gout and tophaceous gout patients, today announced long term treatment data from the Phase 2 trial extension period evaluating patient outcomes up to 18 months of treatment with pozdeutinurad (formerly known as AR882). Detailed results will be presented at the European Alliance of Associations for Rheumatology (EULAR) Congress 2025 meeting, being held June 11-14, 2025, in Barcelona, Spain. 'The long-term data from our Phase 2 trial evaluating pozdeutinurad continues to build on the body of evidence differentiating it as a potentially transformative, best-in-class treatment option for patients with gout and tophaceous gout,' said Arthrosi's Chief Medical Officer Robert T. Keenan, MD, MPH, MBA. 'The significant and sustained reduction in sUA over 18 months observed in both the monotherapy and combination groups demonstrates better efficacy to standard of care alone. In addition, the high response rates of complete tophi resolution as well as rapid resolution of total urate crystal volume represent unprecedented quality of life improvements for patients living with gout. We have already fully enrolled the Phase 3 REDUCE 2 global trial and are rapidly enrolling patients in the ongoing Phase 3 REDUCE 1 trial.' The long term safety and efficacy data will be presented in both oral and poster presentations at EULAR. New Clinical Data for Pozdeutinurad Show: Presentation Details: Title: Sustained Efficacy of Pozdeutinurad (AR882): Long-Term Effect of a Novel and Selective URAT1 Inhibitor in Patients with Chronic Gouty Arthritis. Presenting Author: Robert Keenan, M.D., Chief Medical Officer of Arthrosi Therapeutics Format: Poster presentation Abstract Number: POS1307 Date and Time: Saturday, June 14, 2025, 10:00am-3:00pm CEST Title: Safety and Tolerability of Pozdeutinurad (AR882) Treatment following Long-term Dosing in Patients with Chronic Gouty Arthritis and Subcutaneous Tophi. Presenting Author: Robert Keenan, M.D., Chief Medical Officer of Arthrosi Therapeutics Format: Oral presentation Abstract Number: OP0300 Date and Time: Friday, June 13, 2025, 10:30am CEST About the AR882-203 Phase 2 Study: The Phase 2 study of pozdeutinurad (AR882) in patients with tophaceous gout was a six-month 1:1:1 randomized, global, placebo-controlled study of 42 patients with subcutaneous tophi. The mean baseline sUA among the participants ranged between 9.1-9.6 mg/dL. In the main treatment period, patients received a once daily dose of either 75 mg AR882, 50mg AR882 + allopurinol, or allopurinol up to 300mg. Serum uric acid levels (< 6, <5, <4, or <3 mg/dL) were evaluated monthly through month 6 and continued evaluated up to Month 18, and safety and tolerability were assessed throughout the study. Tophi measurements with calipers were completed every 4 weeks for 6 months and throughout the study. Patients were also imaged using Dual-Energy Computed Tomography (DECT), DECT a specialized imaging technique that is able to differentiate and identify uric acid crystals in the joints and soft tissue, allowing for quantifying uric acid crystal deposition and tophi at baseline, 6, 12, and 18 months. About Gout: In the U.S., an estimated 13 million individuals are diagnosed with gout, ~2 million of which have tophaceous gout. Gout is a form of inflammatory arthritis that can significantly diminish mobility, functionality, and overall quality of life. Gout emerges from the crystallization of uric acid within the joints and soft tissue, instigating painful flare-ups and chronic symptoms. The kidneys play a pivotal role in the process, as they are responsible for filtering out and excreting uric acid from the body. In over 90% of gout patients, underexcretion of uric acid results in the imbalanced and elevated sUA levels that can lead to the deposition of uric acid crystals. It's essential to monitor and manage sUA levels as part of comprehensive gout treatment and prevention strategies. About Arthrosi: Arthrosi Therapeutics, Inc., headquartered in San Diego, CA, is focused on developing pozdeutinurad (AR882), a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares and tophi in patients with gout. Pozdeutinurad has demonstrated encouraging efficacy and safety compared to SOC in Phase 2 studies as well as impressive results in achieving complete resolution of tophi in a Phase 2b study. Arthrosi is currently advancing pozdeutinurad in a pivotal Phase 3 program. Media Contact: Shunqi Yan, PhD Founder & Chief Operating Officer [email protected] Investor Contact: Precision AQ Alex Lobo 212-698-8802 [email protected] View original content to download multimedia: SOURCE Arthrosi Therapeutics

Vytanutra Launches Sustained Release Vitamin C with Iron for Daily Immune Support
Vytanutra Launches Sustained Release Vitamin C with Iron for Daily Immune Support

Yahoo

time43 minutes ago

  • Yahoo

Vytanutra Launches Sustained Release Vitamin C with Iron for Daily Immune Support

IRVINE, Calif., June 12, 2025 /PRNewswire/ -- Vytanutra proudly announces the release of its newest product, Vytanutra C, Ascorbic Acid a scientifically formulated supplement designed to deliver consistent immune and support Collagen Synthesis throughout the day. This advanced formula features Sustained-release Pellet technology, paired with Iron, and is made to meet the needs of modern wellness seekers. Each capsule delivers a steady supply of Vitamin C to help maintain healthy immune function, support collagen production, and provide ongoing protection against oxidative stress. Enhanced with Sustained release coating technology, the beadlets are designed for gradual release and optimal stability, helping preserve potency and ensure consistent absorption over time. Key Features: • Extended-Release Pellet System – The spherical pellet is designed to enlarge the absorption area in the GI tract and deliver Vitamin C steadily for 12 hours, helping maintain a stable plasma concentration in the blood. • Non-GMO, Vegan, and Gluten-Free – Clean and conscious formulation suitable for various dietary needs Each bottle contains 90 Pellet capsules, making it a convenient and reliable choice for individuals seeking daily immune system support with long-lasting effects. Now Available on AmazonVisit the Vytanutra Amazon Store and search "Vytanutra C" to explore the latest in immune support innovation. Stay strong. Stay resilient. Experience all-day wellness with Vytanutra Immune Support Vitamin C. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Contact:Sean TangAccount Manager396609@ View original content to download multimedia: SOURCE Vytanutra

Datavant to Acquire Ontellus to Transform Medical Record Retrieval with Tech-Enabled Health Records Retrieval and Claims Intelligence Solutions
Datavant to Acquire Ontellus to Transform Medical Record Retrieval with Tech-Enabled Health Records Retrieval and Claims Intelligence Solutions

Business Wire

timean hour ago

  • Business Wire

Datavant to Acquire Ontellus to Transform Medical Record Retrieval with Tech-Enabled Health Records Retrieval and Claims Intelligence Solutions

NEW YORK--(BUSINESS WIRE)-- Datavant, a leading health data platform company, today announced that it has signed an agreement to acquire Ontellus, a leading provider of health records retrieval and claims intelligence from Aquiline, a private investment firm specializing in financial services and technology and Capstreet, a Houston-based lower middle market private equity firm. With this acquisition, Ontellus will join Datavant to deliver an integrated, digital-first platform that connects those with health records to those who need them easily, quickly and securely. In addition to driving value to providers, freeing up more of their time to focus on patient care, this acquisition will transform the experience for requesters from a largely manual and time consuming process to a more efficient, digital process. The combined organization will reduce administrative burden for Datavant's network of over 80,000 health care providers, clinics, hospitals and health system partners, who routinely manage requests for health records—vital for life insurance underwriting, injury claims, and legal case work. Today, the record retrieval process remains highly fragmented, with inconsistent workflows, procedures, and data formats across thousands of organizations. By joining forces, Datavant and Ontellus reaffirm their shared commitment to simplify this complexity and improve access to records to ensure that confidential health records are digitized in a secure and timely manner to authorized parties. 'Moving health data securely and compliantly from where it sits to where it needs to be in the right format to authorized users is one of the industry's biggest challenges,' said Datavant CEO Kyle Armbrester. 'In addition to driving value to our health care providers, freeing up more of their time to focus on patient care, this acquisition will transform the experience for requesters from a largely manual and time consuming process to a more efficient, digital process that leverages Datavant's deep expertise in privacy preservation and compliance. We are delighted to welcome Ontellus' world-class team and work with them to further transform the health data request process for all of our customers.' Ontellus has digitized its records retrieval business into a nationwide platform through which record requestors have direct access to providers. Additionally, through its canvassing services, Ontellus delivers detailed claimant treatment timelines to validate claims or uncover preexisting conditions, helping customers reduce unnecessary and costly claims exposure. Datavant will join Ontellus' capabilities with its own digital connectivity capabilities to create a highly tech-enabled integrated platform offering to better serve all customers. Ontellus CEO, Vince Cole, will join Datavant's Executive Leadership Team, reporting directly to Kyle Armbrester, Datavant CEO. 'By combining Ontellus' industry-leading request fulfillment infrastructure with Datavant's advanced connectivity and data exchange capabilities, we're enabling faster, more precise access to critical health information—not only for healthcare providers, but also for legal and insurance professionals who rely on timely, accurate data to support claims and compliance. We are deeply grateful to our investor partners, Aquiline Capital Partners and The Capstreet Group, whose strategic guidance and resources have powered our growth and product innovation,' said Vince Cole, CEO of Ontellus. Houlihan Lokey served as buyside financial advisor to Datavant, assisting in evaluating and negotiating the acquisition. Harris Williams is the sell-side advisor to Ontellus, representing the company in its pending sale to Datavant. About Datavant Datavant is a health data platform company. We make the world's health data secure, accessible, and actionable. Datavant drives data connectivity into action by offering a proprietary platform and network that deliver critical solutions across the healthcare ecosystem. Datavant enables more than 60 million healthcare records to move between thousands of organizations, more than 80,000 hospitals and clinics, 75% of the 100 largest health systems, and an ecosystem of 300+ real-world data partners. To learn more about Datavant, visit and follow us on LinkedIn. About Ontellus Ontellus empowers insurance carriers, self-insured corporations and law firms to reduce costs, make informed decisions and accelerate claims resolution. As one of the nation's largest, privately held data retrieval and claims intelligence providers, Ontellus leverages decades of experience and cutting-edge technology to deliver impactful products and client-centric services with industry-leading turnaround times. For more information, visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store